DR. MARK PHILIPS, MD
Osteopathic Medicine at 1 Ave, New York, NY
License number
New York 156806
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
462 1St Ave #A-560, New York, NY 10016
Phone
(212) 562-2300
(212) 562-3486 (Fax)
(212) 562-3486 (Fax)
Personal information
See more information about MARK PHILIPS at radaris.comName
Address
Phone
72 Oyster Shores Rd, East Hampton, NY 11937
708 Greenwich St APT 2G, New York, NY 10014
72 Oyster Shores Rd, East Hampton, NY 11937
1480 Washington Ave, Bronx, NY 10456
11 Richards St, Massena, NY 13662
Organization information
See more information about MARK PHILIPS at bizstanding.comMark Philips MD
550 1 Ave, New York, NY 10016
Industry:
Internist
Phone:
(212) 562-6497 (Phone)
Mark Reid Philips
Professional information
Dr. Mark Philips, New York NY - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
462 1St Ave SUITE A-560, New York 10016
(212) 562-2300 (Phone), (212) 562-3486 (Fax)
NYU MEDICAL CENTER
550 1St Ave SUITE 1, New York 10016
(212) 263-6403 (Phone), (212) 263-8804 (Fax)
(212) 562-2300 (Phone), (212) 562-3486 (Fax)
NYU MEDICAL CENTER
550 1St Ave SUITE 1, New York 10016
(212) 263-6403 (Phone), (212) 263-8804 (Fax)
Certifications:
Internal Medicine, 1985, Rheumatology, 1988
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1982
Bellevue Hospital Center
Nyu Langone Medical Center
Columbia University / College of Physicians And Surgeons
Graduated: 1982
Bellevue Hospital Center
Nyu Langone Medical Center
Mark Philips, New York NY
Specialties:
Rheumatologist
Address:
550 1St Ave, New York, NY 10016
462 1St Ave, New York, NY 10016
462 1St Ave, New York, NY 10016
Education:
Columbia University, College of Physicians and Surgeons - Doctor of Medicine
Bellevue Hospital Center - Residency - Internal Medicine
Bellevue Hospital Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Rheumatology (Internal Medicine)
Antibodies To Polypeptides Having Prenylcysteine Carboxyl Methlytransferase Activity Or Inhibiting Activity
US Patent:
6432403, Aug 13, 2002
Filed:
Nov 8, 2000
Appl. No.:
09/708015
Inventors:
Mark R. Philips - New York NY
Assignee:
New York University - New York NY
International Classification:
A61K 3900
US Classification:
4241341, 5303873, 53038826, 5303891, 5303911, 5303913, 5303917
Abstract:
An antibody specific for the mammalian protein prenylcysteine carboxyl methyltransferase.
Mark Philips, New York NY - Landlord
Work:
united states of america
New York
(447) 024-0800
New York
(447) 024-0800
Prenyl-Electrostatic Switch, And Methods Of Use
US Patent:
7767417, Aug 3, 2010
Filed:
Apr 19, 2005
Appl. No.:
11/109262
Inventors:
Mark R. Philips - New York NY, US
Trever G. Bivona - New York NY, US
Trever G. Bivona - New York NY, US
Assignee:
New York University - New York NY
International Classification:
C12P 21/06, A61K 38/48, A61K 39/395, C07H 21/04, C07K 14/32
US Classification:
435 691, 4241381, 4241551, 435325, 530350, 5303888, 514 12
Abstract:
The present invention relates to a method of identifying compounds as candidate drugs for treatment of cancer by providing a cell expressing a GTPase protein that is regulated by a prenyl-electrostatic switch, contacting the cell with compounds to be evaluated, and selecting compounds able to regulate charge at the prenyl-electrostatic switch in the GTPase protein as candidate drugs for treatment of cancer. Also disclosed are methods of treating cancer in a patient. An isolated antibody which binds to a phosphorylated prenyl-electrostatic switch on a K-Ras4B protein is also disclosed, as is a kit for detecting phosphorylation of a prenyl-electrostatic switch in a K-Ras4B protein which includes a labeled antibody and a device to detect the label. Also disclosed is a method of detecting phosphorylation of a prenyl-electrostatic switch on a K-Ras4B protein in a biological sample.
Quantitative Assay For Membrane Association Of Proteins
US Patent:
2012006, Mar 15, 2012
Filed:
Aug 31, 2011
Appl. No.:
13/222620
Inventors:
Mark R. PHILIPS - New York NY, US
Nicole FEHRENBACHER - New York NY, US
Joseph WYNNE - New York NY, US
Nicole FEHRENBACHER - New York NY, US
Joseph WYNNE - New York NY, US
Assignee:
NEW YORK UNIVERSITY - New York NY
International Classification:
C12Q 1/66, A01K 67/027, C12Q 1/02
US Classification:
800 18, 435 8, 435 29, 800 13, 800 14
Abstract:
The present invention relates to a kit for detection of association of a peripheral cellular membrane binding protein with cellular membranes in living cells and methods thereof. The kit includes a first nucleic acid construct comprising a first nucleic acid molecule encoding a first fusion protein comprising a peripheral cellular membrane binding protein or membrane binding domain thereof operatively coupled to DNA binding and transactivation domains of a naturally occurring or chimeric transcription factor and a first promoter operatively associated with the first nucleic acid molecule. A second nucleic acid construct comprises a second nucleic acid molecule encoding a reporter protein and a second promoter responsive to the DNA binding and transactivation domains of the first fusion protein. The second promoter is operatively associated with the second nucleic acid molecule. Activation of the second promoter results in expression of the reporter protein. Also disclosed is a transgenic non-human animal.
Polypeptides Having Prenylcysteine Carboxyl Methyltransferase Activity Or Inhibiting Activity
US Patent:
6184016, Feb 6, 2001
Filed:
Jun 11, 1998
Appl. No.:
9/095758
Inventors:
Mark R. Philips - New York NY
Assignee:
New York University - New York NY
International Classification:
C12N 910, C12Q 148
US Classification:
435193
Abstract:
A mammalian protein, prenylcysteine carboxyl methyltransferase, involved in further post-translational modification of prenylated proteins, is cloned, characterized, and expressed in non-native cells. Such membrane preparations can be used to screen for inhibitors of prenylcysteine carboxyl methyltransferase activity.
Prenylcysteine Carboxyl Methyltransferase, Dna Encoding Same, And A Method Of Screening For Inhibitors Thereof
US Patent:
6232108, May 15, 2001
Filed:
Oct 22, 1999
Appl. No.:
9/422968
Inventors:
Mark R. Philips - New York NY
Assignee:
New York University - New York NY
International Classification:
C12N 910, C12N 1500, C12N 120, C12Q 168, C07H 2104
US Classification:
435193
Abstract:
A mammalian protein, prenylcysteine carboxyl methyltransferase, involved in further post-translational modification of prenylated proteins, is cloned, characterized, and expressed in non-native cells. Such membrane preparations can be used to screen for inhibitors of prenylcysteine carboxyl methyltransferase activity.
Single Wall Nanotube Constructs And Uses Therefor
US Patent:
8540965, Sep 24, 2013
Filed:
Jul 31, 2006
Appl. No.:
11/989672
Inventors:
David A. Scheinberg - New York NY, US
Michael McDevitt - Bronx NY, US
Christophe Antczak - New York NY, US
Debjit Chattopadhyay - Pennington NJ, US
Rena May - Richmond VA, US
Jón Njardarson - Ithaca NY, US
Mark Reid Philips - New York NY, US
Michael McDevitt - Bronx NY, US
Christophe Antczak - New York NY, US
Debjit Chattopadhyay - Pennington NJ, US
Rena May - Richmond VA, US
Jón Njardarson - Ithaca NY, US
Mark Reid Philips - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York City NY
International Classification:
A61K 49/00
US Classification:
424 91, 424 93, 424 932, 424 9322, 424 934
Abstract:
The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.